International Journal of Pharmacy and Pharmaceutical Science

ISSN Print: 2664-7222
ISSN Online: 2664-7230
IJPPS 2025; 7(2): 186-191
www.pharmacyjournal.org
Received: 03-06-2025
Accepted: 06-07-2025

Senthil Prabhu R
Department of Pharmaceutics, College of pharmacy, Madurai Medical College, Madurai, Tamil Nadu, India

Uma Maheshwari D
Department of Pharmaceutics, College of pharmacy, Madurai Medical College, Madurai, Tamil Nadu, India

Kavya B
PG Scholar, Department of Pharmaceutics, College of pharmacy, Madurai Medical College, Affiliated to The Tamil Nadu Dr. M.G.R. Medical university, Chennai, Tamil Nadu, India

Abinaya R
PG Scholar, Department of Pharmaceutics, College of pharmacy, Madurai Medical College, Affiliated to The Tamil Nadu Dr. M.G.R. Medical university, Chennai, Tamil Nadu, India

Ayisha Siddiqa AR
PG Scholar, Department of Pharmaceutics, College of pharmacy, Madurai Medical College, Affiliated to The Tamil Nadu Dr. M.G.R. Medical university, Chennai, Tamil Nadu, India

Sivanesan B
PG Scholar, Department of Pharmaceutics, College of pharmacy, Madurai Medical College, Affiliated to The Tamil Nadu Dr. M.G.R. Medical university, Chennai, Tamil Nadu, India

Corresponding Author:
Senthil Prabhu R
Department of Pharmaceutics, College of pharmacy, Madurai Medical College, Madurai, Tamil Nadu, India

Assimilation of ai softwares in the design and development of personalized transdermal drug delivery platforms

Senthil Prabhu R, Uma Maheshwari D, Kavya B, Abinaya R, Ayisha Siddiqa AR and Sivanesan B

DOI: https://doi.org/10.33545/26647222.2025.v7.i2c.208

Abstract
Personalized Transdermal Drug Delivery Systems (PTDDS) represent a transformative advancement in precision medicine, enabling tailored drug administration based on individual patient characteristics. With the integration of advanced software tools, machine learning (ML), and deep learning (DL) algorithms, PTDDS are evolving from static platforms into intelligent, adaptive drug delivery systems. Software such as COMSOL Multiphysics, MATLAB, and Simcyp facilitate in silico modeling of skin permeation and pharmacokinetics, while AI platforms like TensorFlow, Scikit-learn, and PyTorch are employed to develop predictive models for dose optimization and patient stratification. Wearable biosensors integrated with smart patches can collect real-time physiological data, which can be analyzed using ML models to dynamically modulate drug release. This convergence of pharmaceutical sciences with data-driven technologies not only enhances therapeutic outcomes but also minimizes adverse effects by enabling patient-specific dosing. Despite significant progress, challenges remain in algorithm validation, data standardization, device integration, and regulatory acceptance. This review highlights the synergy between transdermal drug delivery systems and intelligent software technologies, with emphasis on recent advancements, practical applications, and future directions in the development of AI-powered personalized drug delivery platforms.

Keywords: Personalized medicine, Transdermal drug delivery, Machine learning, Deep learning, Software tools, AI in healthcare

Introduction
Transdermal Drug Delivery Systems (TDDS) offer significant advantages over traditional oral and injectable routes by enabling medicines to percolate through the skin and enter systemic rotation [1]. One of the primary benefits of TDDS is the bypass of first- pass metabolism in the liver, which frequently leads to the declination of active medicine composites, reducing their bioavailability. also, TDDS enables controlled and sustained medicine release, icing that remedial medicine situations are maintained over an extended period, thereby perfecting patient compliance by reducing the frequence of administration [2]. This is particularly profitable for habitual conditions where harmonious, long- term medicine remedy is necessary. Another advantage of TDDS is its capability to givenon-invasive medicine delivery, reducing the need for injections and minimizing patient discomfort. The ease of use of TDDS, combined with its accessible, discreet administration, makes it a favored system for numerous cases who struggle with lozenge- taking or regular injections [3]. likewise, it avoids the variability of medicine immersion that can do with oral routes due to factors like food input and gastrointestinal motility. still, the efficacity of TDDS is constrained by several critical factors. The stratum corneum, the remotest subcaste of the skin, acts as a robust hedge to medicine saturation. Its low permeability restricts the passage of numerous medicines, particularly large and hydrophilic motes [4]. This poses a challenge for medicines that bear high bioavailability or those that need to be administered at precise tablets. As a result, innovative strategies similar as penetration enhancers, lipid- grounded

carriers, or microneedle arrays are frequently employed to ameliorate skin saturation. Advanced delivery systems that incorporate technologies like nanoencapsulation or electroporation are also being explored to enhance medicine immersion through the skin [5]. likewise, formulating effective TDDS systems involves a delicate balance between medicine stability, release kinetics, and comity with skin physiology. The medicine must remain stable within the patch and release at a rate that ensures remedial effectiveness over the intended duration. The expression also needs to consider the commerce between the patch accoutrements (similar as bonds and polymers) and the skin to help vexation or antipathetic responses. also, factors like skin hydration, temperature, and age- related changes in skin parcels can impact the performance of the delivery system, farther complicating the development of universal results [6]. Over the once decade, exploration and technological advancements in Transdermal Drug Delivery Systems (TDDS) have significantly expanded, reflecting a growing global interest in prostrating the challenges associated with these systems [7]. multitudinous exploration papers have been published, and innovative technologies have been developed, pressing progress in the field. Studies indicate a substantial increase in TDDS- related exploration, particularly concentrated on limitations similar as skin permeability and the delivery of macromolecular medicines. ways similar as microneedles, chemical penetration enhancers (CPEs), and nanotechnology have gained considerable exploration attention [8].

Microneedles, for example, have been extensively studied for various applications, including vaccine delivery and pain management, making them a central focus of TDDS research. Research on microneedles for vaccine delivery has significantly increased in recent years, with advancements in materials, fabrication techniques, and integration with biologics, further enhancing the role of TDDS in non-invasive, patient-friendly vaccine administration. The integration of emerging technologies, such as nanocarriers (liposomes and nanoparticles), has also transformed TDDS, improving drug stability and enabling targeted delivery for specific applications in areas like cancer and dermatology [9]. In addition to microneedles and nanotechnology, techniques like electroporation, photomechanical waves, and thermal ablation have been explored to temporarily disrupt the skin barrier, facilitating molecule delivery. These methods enable rapid and localized drug administration, expanding the range of conditions that can be treated with TDDS [10]. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) is emerging as a transformative trend in TDDS, enabling formulation optimization, real-time adjustments, and more patient-specific solutions. This fusion of cutting-edge technologies promises to further revolutionize non-invasive drug delivery [11].

To advance the development of modern TDDS for effective disease treatment, the use of predictive computational models that simulate material interactions and the drug's skin permeability and release profile over time has become increasingly crucial. These models can save time and resources by providing accurate simulations that guide the design of more efficient and effective drug delivery systems. Over the last decade, the integration of computational technology has increasingly played a significant role in developing innovative, targeted delivery systems, driving the field toward more personalized and adaptive drug delivery solutions [12].

Utilization of artificial intelligence, machine learning in PTDDS

As we advance into a new century defined by groundbreaking technological innovations, Machine Learning (ML) and Artificial Intelligence (AI) have risen to the forefront as powerful tools for managing and analyzing scientific data. The advent of AI and ML has led to transformative changes across multiple sectors, with the pharmaceutical industry being one of the primary beneficiaries [13]. AI, a term first coined by John McCarthy in 1956, refers to the ability of machines to replicate human cognitive abilities, such as learning, reasoning, and problem-solving, translating complex data sets into meaningful insights. AI systems are designed to mimic human thought processes, enabling them to process and interpret large volumes of data, offering valuable solutions to complex challenges [14]. In recent years, the synergy between AI and Machine Learning has begun reshaping the landscape of Transdermal Drug Delivery Systems (TDDS) research and development. These technologies have revolutionized the way TDDS formulations are designed and optimized by utilizing AI's capacity to analyze vast amounts of data efficiently. AI algorithms can predict drug-skin interactions, model the permeation behavior of drugs through the skin, and assess the impact of excipients on drug delivery [15]. Additionally, AI can assist in optimizing the physical and chemical properties of delivery systems,ensuring their effectiveness and compatibility with skin physiology. The profound ability of AI to process diverse information—from genetic data to clinical outcomes—has enabled it to significantly accelerate the drug development process, which traditionally takes many years. By leveraging AI's capacity to analyze patterns within large datasets, researchers can now optimize drug formulations faster, reduce trial and error in preclinical and clinical stages, and identify the most promising drug candidates for clinical applications [16]. AI's role extends beyond mere prediction; it offers personalized, adaptive solutions to drug delivery, enabling precision medicine tailored to individual patient needs. Incorporating AI into the TDDS research pipeline enhances formulation efficiency, reduces costs, and shortens time-to-market for new therapies. The fusion of AI with traditional drug development processes is an exciting paradigm shift, one that is poised to reshape how we approach drug delivery systems, bringing innovations that will improve both therapeutic efficacy and patient outcomes [17].

Applications of deep neural network (DNN) IN PTDDS

Artificial Intelligence (AI), particularly through deep neural network (DNN) models, has demonstrated powerful capabilities in the detection of skin diseases and the prediction of skin conditions using digital imaging. These AI-assisted diagnostics provide critical information during the early stages of drug discovery and formulation development, allowing researchers to make informed decisions about therapeutic approaches. One of the most promising areas where AI is making a significant impact is in the formulation design and optimization of transdermal systems. By analyzing complex datasets, AI can assist in selecting smart drug carriers tailored for dermal delivery, a growing trend not only in treating skin-related diseases but also in advancing cosmetic and skincare technologies [18].

Accurately predicting drug deposition within the skin from various transdermal drug delivery systems (TDDS) is crucial for developing effective formulations. Traditional approaches to these predictions often require time-consuming *in vivo* or *in vitro* testing. However, with the integration of AI and machine learning (ML) algorithms, researchers can now generate predictive models that yield highly accurate simulations, saving both time and resources. These models provide actionable insights for identifying the optimal formulation strategies and improving therapeutic outcomes [19].

Several dynamic AI and ML-based computational models have emerged as key tools in pharmaceutical research. For example, BIOiSIM, a pharmacokinetic prediction model, helps simulate drug exposure and distribution within the body. COMSOL Multiphysics, another widely used platform, enables the simulation of factors such as temperature effects on drug absorption through the skin. Additionally, Artificial Neural Network (ANN) models have been applied in real-time scenarios—for instance, in predicting the efficacy of drugs during the COVID-19 pandemic. Other ML models, such as K-Nearest Neighbors (KNN), Support Vector Machines (SVM), and Deep Neural Networks (DNN), have also been utilized to predict active protease inhibitor sites, particularly in the treatment of HIV-1, highlighting their versatility across different therapeutic areas.

Moreover, AI-driven innovation extends beyond software modeling into the realm of smart transdermal devices. These next-generation delivery platforms are capable of real-time physiological monitoring and can adjust drug release rates dynamically based on patient-specific parameters. Such adaptability ensures consistent therapeutic levels, enhances safety, and supports the development of truly personalized drug delivery systems. The integration of AI with TDDS not only overcomes many of the limitations of conventional methods—such as poor skin permeability and lack of dosage [20].

Table 1: list of softwares used in personalized transdermal drug delivery systems

S. No	Software name	Developers	Year/origin	Applications
1.	COMSOL Multiphysics® [21]	Pär Olofsson	1986/Sweden	• Modeling skin permeation dynamics using diffusion equations. • Simulating drug release kinetics from transdermal patches. • Thermal effect analysis on transdermal absorption efficiency. • Geometry and formulation optimization for patch design.
2.	MATLAB® (Matrix Laboratory) [22]	Cleve Moler, Jack Little, and Steve Bangert	1984/USA	• Data analysis and result interpretation • Graph plotting and visualization. • Mathematical modeling of drug kinetics • Optimization of formulation parameters • Simulation of drug delivery systems
3.	SIMCYP SIMULATOR [23]	Certara®	2012/UK	• Prediction of human pharmacokinetics (PK) using *in vitro* and in silico data. • Modeling transdermal absorption and skin permeability • Simulation drug-drug interaction (DDIs) and their impact on drug delivery • Personalized dose optimization for specific populations (e.g., geriatric, pediatric
4.	BIOiSIM [24]	Verisimlife	2017/San Francisco, California, USA	• AI-powered pharmacokinetic (PK) and pharmacodynamic (PD) predictions. • Modeling pharmacokinetics (PK) and pharmacodynamics (PD) of drugs. • Prediction of dose-response relationships in various populations. • Design and optimization of drug formulations based on virtual trials.
5.	GastroPlus® [25]	Simulations Plus, Inc.	1996/USA	• Predicts drug absorption and bioavailability • Helps in optimizing drug formulations. • Simulates pharmacokinetics using PBPK modeling • Supports regulatory submissions with virtual trials
6.	PK-Sim [26]	Open Systems Pharmacology (OSP)	2012/Germany	• Predicts drug concentration – time profile in plasma and tissues. • Supports physiologically based pharmacokinetics (PBPK) modeling • Assesses drug behavior in special populations (e. g., pediatrics, elderly) • Simulates drug-drug interactions and variability between individuals
7.	MoBi [27]	Open Systems Pharmacology (OSP)	2012/Germany	• Builds detailed systems biology models combining drug kinetics and biological processes. • Enhances PBPK models with complex mechanistic pathways (e. g., signalling, gene expression). • Allows users to design new compartments and reactions beyond default PK Structures.

				• Supports drug action modeling at the molecular or cellular level for deeper insights.
8.	TensorFlow	Google Brain Team	2015/US	• Used for building and training deep learning models like neural networks. • Applied in image and speech recognition systems. • Powers natural language processing tasks like translation and chatbots. • Supports predictive analytics in healthcare and finance

Leading marketed softwares in the development of PTDDS



Fig 1: MATLAB

Fig 2: COMSOL

Fig 3: SIMCYP

Fig 4: BIOSIM

Fig 5: GastroPlus®

Fig 6: TensorFlow

Fig 7: PK-Sim, MoBi

Artificial inteligence in healthcare systems

Artificial Intelligence (AI) has surfaced as a transformative force in ultramodern healthcare, revolutionizing the opinion, treatment, and operation of conditions. By leveraging vast and complex datasets, AI systems especially those powered by machine learning (ML) and deep learning (DL) are enabling unprecedented advancements in personalized medicine, clinical decision support, medical imaging, and patient monitoring. AI algorithms can process multi-dimensional health data, including genomics, proteomics, radiological images, and electronic health records (EHR), to uncover patterns that guide precision diagnosis and prognostic predictions [28].

In diagnostics, deep learning models such as convolutional neural networks (CNNs) are now capable of identifying anomalies in radiological scans with performance comparable to or exceeding that of trained radiologists [29]. In predictive analytics, ML models can forecast hospital readmission risks, disease progression, and patient outcomes, aiding clinicians in proactive intervention. Natural language processing (NLP) techniques are being deployed to extract meaningful insights from unstructured clinical notes, improving EHR utility [30].

AI also plays a pivotal role in drug discovery and development, where algorithms accelerate target identification, compound screening, and toxicity prediction. In robotic surgery, AI enables real-time adjustments and precision in minimally invasive procedures [31]. Moreover, AI-integrated wearable technologies continuously monitor physiological parameters—such as ECG, glucose levels, and blood pressure—allowing early detection of health deviations and enabling real-time response mechanisms.

Despite its enormous potential, the deployment of AI in healthcare faces several challenges, including data privacy concerns, algorithmic bias, lack of standardized validation protocols, and regulatory hurdles. Addressing these limitations is essential to ensure ethical, safe, and equitable integration of AI technologies into healthcare systems [32].

Conclusion

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into personalized transdermal drug delivery systems (PTDDS) is revolutionizing the pharmaceutical field. These technologies allow for the design of intelligent drug delivery platforms that adapt to individual patient needs by analyzing biological data, predicting drug permeation through the skin, and dynamically adjusting drug release. Moreover, AI facilitates the simulation of pharmacokinetic profiles, accelerates formulation development, and reduces the time and cost associated with clinical trials. As wearable biosensors and smart patches continue to evolve, their real-time data integration with AI algorithms will pave the way for closed-loop, personalized therapeutics. To truly realize the potential of PTDDS,future efforts must focus on data standardization, regulatory alignment, and interdisciplinary collaboration.

Conflict of interest

The authors have no conflicts of interest regarding this investigation.

Acknowledgments
The authors would like to thank Dean, Madurai Medical College, Principal, College of Pharmacy, Madurai Medical College and all other lab studies.

References

1. Alkilani AZJ, Hamed R, Nimrawi S, Hussein G, Abo-Zour H, Donnelly RF. Beneath the skin: a review of current trends and future prospects of transdermal drug delivery systems. Pharmaceutics. 2022 May 28;14(6):1152.
2. Zaid Alkilani A, McCrudden MT, Donnelly RF. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015 Oct 22;7(4):438-70.
3. Jeong WY, Kwon M, Choi HE, Kim KS. Recent advances in transdermal drug delivery systems: A review. Biomaterials research. 2021 Jul 28;25(1):24.
4. Kumar N, Dubey A, Mishra A, Tiwari P. Ethosomes: A novel approach in transdermal drug delivery system. International journal of pharmacy & life sciences. 2020 May 1;11(5).
5. Prausnitz MR. A practical assessment of transdermal drug delivery by skin electroporation. Advanced drug delivery reviews. 1999 Jan 4;35(1):61-76.
6. Phatale V, Vaiphei KK, Jha S, Patil D, Agrawal M, Alexander A. Overcoming skin barriers through advanced transdermal drug delivery approaches. Journal of controlled release. 2022 Nov 1;351:361-80.
7. Ramadon D, McCrudden MT, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: Current trends and applications. Drug delivery and translational research. 2022 Apr;12(4):758-91.
8. Sala M, Diab R, Elaissari A, Fessi H. Lipid nanocarriers as skin drug delivery systems: Properties, mechanisms of skin interactions and medical applications. International journal of pharmaceutics. 2018 Jan 15;535(1-2):1-7.
9. Patel BA. Permeation enhancement and advanced strategies: A comprehensive review of improved topical drug delivery. International Research Journal of Modernization in Engineering Technology and Science. 2024;6(05):6691-702.
10. Goswami DS, Uppal N, Goyal S, Mehta N, Gupta AK. Permeation enhancer for TDDS from natural and synthetic sources: A review. J. Biomed. Pharm. Res. 2013;2(1):19-29.
11. Matharoo N, Mohd H, Michniak-Kohn B. Transferosomes as a transdermal drug delivery system: Dermal kinetics and recent developments. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2024 Jan;16(1):e1918.
12. Xue Y, Chen C, Mi X, Tan R, Wang J, Wu S, *et al*. Transdermal drug delivery system: current status and clinical application of microneedles. ACS Materials Letters. 2024 Feb 2;6(3):801-21.
13. Elder A, Cappelli MO, Ring C, Saedi N. Artificial intelligence in cosmetic dermatology: An update on current trends. Clinics in Dermatology. 2024 May 1;42(3):216-20.
14. Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. Advanced drug delivery reviews. 2019 Nov 1;151:169-90.
15. Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine learning in drug discovery: a review. Artificial intelligence review. 2022 Mar;55(3):1947-99.
16. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023 Jul 10;15(7):1916.
17. Antontsev V, Jagarapu A, Bundey Y, Hou H, Khotimchenko M, Walsh J, *et al*. A hybrid modeling approach for assessing mechanistic models of small molecule partitioning *in vivo* using a machine learning-integrated modeling platform. Scientific Reports. 2021 May 27;11(1):11143.
18. LaCount TD, Zhang Q, Hao J, Ghosh P, Raney SG, Talattof A, *et al*. Modeling temperature-dependent dermal absorption and clearance for transdermal and topical drug applications. The AAPS journal. 2020 May 10;22(3):70.
19. Shanbehzadeh M, Nopour R, Kazemi-Arpanahi H. Developing an artificial neural network for detecting COVID-19 disease. Journal of education and health promotion. 2022 Jan 1;11(1):2.
20. Li Y, Tian Y, Qin Z, Yan A. Classification of HIV-1 protease inhibitors by machine learning methods. ACS omega. 2018 Nov 21;3(11):15837-49.
21. Schäfer A, Pecha U, Kaiser B, Schmid M, Parspour N. Accelerated 3D FEA of an axial flux machine by exclusively using the magnetic scalar potential. Energies. 2023 Sep 13;16(18):6596.
22. Costa AN, Dantas JP, Scukins E, Medeiros FL, Ã–gren P. Simulation and Machine Learning in Beyond Visual Range Air Combat: A Survey. IEEE Access. 2025 Apr 23.
23. Saldanha L, Vale N. The First Physiologically Based Pharmacokinetic (PBPK) Model for an Oral Vaccine Using Alpha-Tocopherol as an Adjuvant. Pharmaceutics. 2023 Sep 13;15(9):2313.
24. 24.Ibarra M, Schiavo A, Lesko LJ. Physiologically based pharmacokinetic (PBPK) modeling: software. InThe ADME Encyclopedia: A Comprehensive Guide on Biopharmacy and Pharmacokinetics 2022 Jun 15 (pp. 995-1004). Cham: Springer International Publishing.
25. Zhang Z, Tell LA, Lin Z. Comparisons of PK-Sim and R program for physiologically based pharmacokinetic model development for broiler chickens and laying hens: meloxicam as a case study. Toxicological Sciences. 2025 May;205(1):28-41.
26. Sokolov V, Peskov K, Helmlinger G. A Framework for Quantitative Systems Pharmacology Model Execution.
27. Ganegedara T. TensorFlow in action. Simon and Schuster; 2022 Oct 18.
28. Dilsizian SE, Siegel EL. Artificial intelligence in medicine and cardiac imaging: harnessing big data and advanced computing to provide personalized medical diagnosis and treatment. Current cardiology reports. 2014 Jan;16(1):441.
29. Patel VL, Shortliffe EH, Stefanelli M, Szolovits P, Berthold MR, Bellazzi R, *et al*. The coming of age of artificial intelligence in medicine. Artificial intelligence in medicine. 2009 May 1;46(1):5-17.

30. Jha S, Topol EJ. Adapting to artificial intelligence: radiologists and pathologists as information specialists. Jama. 2016 Dec 13;316(22):2353-2354.
31. Pearson T. How to replicate Watson hardware and systems design for your own use in your basement. IBM: Watson, MN, USA. 2011 Jun 1.
32. Prabhu RS, Ananthi DS, Rajasoundarya S, Janakan R, Priyanka R. Internet of nanothings (IoNT)–A concise review of its healthcare applications and future scope in pandemics.